STAMAN, JAMES MD
Ophthalmology · NPI 1841290657 · JACKSONVILLE, FL
STAMAN, JAMES is a Ophthalmology in JACKSONVILLE, FL, a member of 1 medical group, who billed 23 distinct codes to Medicare Part B in 2024.
Groups: RETINA VITREOUS CONSULTANTS (FT LAUDERDALE, FL)
Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒
Provider overview · all codes · CY2024
All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.
Procedures billed to Medicare Part B (2024)
Medicare Part B FFS · CY2024 · as published by CMS| Code | Description | Services | Beneficiary-episodes | Avg charge | Avg Medicare payment |
|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | premium | premium | premium | premium |
| J0177 | Injection, aflibercept hd, 1 mg | premium | premium | premium | premium |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | premium | premium | premium | premium |
| 67028 | Injection of drug into eye | premium | premium | premium | premium |
| 92134 | Imaging of retina | premium | premium | premium | premium |
| 92250 | Photography of the retina | premium | premium | premium | premium |
| J0178 | Injection, aflibercept, 1 mg | premium | premium | premium | premium |
| 92014 | Established patient complete exam of visual system | premium | premium | premium | premium |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | premium | premium | premium | premium |
| 99213 | Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | premium | premium | premium | premium |
| 92004 | New patient complete exam of visual system | premium | premium | premium | premium |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | premium | premium | premium | premium |
| J0179 | Injection, brolucizumab-dbll, 1 mg | premium | premium | premium | premium |
| J3490 | Unclassified drugs | premium | premium | premium | premium |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | premium | premium | premium | premium |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | premium | premium | premium | premium |
| J7999 | Compounded drug, not otherwise classified | premium | premium | premium | premium |
| 76512 | 2d ultrasound scan of eye tissue and structures | premium | premium | premium | premium |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | premium | premium | premium | premium |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | premium | premium | premium | premium |
| 67515 | Injection of drug or substance into membrane covering eyeball | premium | premium | premium | premium |
| 92012 | Established patient problem focused exam of visual system | premium | premium | premium | premium |
These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.